Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis
Anti-angiogenic agents and immunotherapy are the cornerstone of advanced/metastatic renal-cell carcinoma (mRCC) treatment. Recently, the therapeutic scenario of first-line therapy for mRCC has been completely revolutionized. The combination of the two immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab (targeting PD-1 and CTLA4, respectively) yielded a significant survival advantage, compared to sunitinib, in International Metastatic RCC Database consortium (IMDC) intermediate- and poor-risk patients, but failed to improve outcomes of favorable-risk patients [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 18, 2021 Category: Cancer & Oncology Authors: C. Ciccarese, R. Iacovelli, C. Porta, G. Procopio, E. Bria, S. Astore, MA. Cannella, G. Tortora Source Type: research
Late Hepatic Toxicity Surveillance for Survivors of Childhood, Adolescent and Young Adult Cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Advances in the treatment of childhood, adolescent and young adult (CAYA) cancer have greatly improved 5-year survival, which now exceeds 80% [1 –3]. Unfortunately, many survivors experience long-term morbidity and early mortality resulting from their cancer and/or its treatment [4–6]. Although uncommon, hepatic late complications can lead to substantial morbidity, quality of life impairment and even early mortality. In the Childhood Can cer Survivor Study cohort, the rate of self-reported liver cirrhosis in North American adult survivors of CAYA cancer was 0.2 per 1000 person-years, which was 9 times higher than in si...
Source: Cancer Treatment Reviews - September 18, 2021 Category: Cancer & Oncology Authors: Edit Bardi, Ren ée L Mulder, Elvira C van Dalen, Neel S Bhatt, Kathy A Ruble, Jennifer Burgis, Sharon M Castellino, Louis S Constine, Caroline M den Hoed, Daniel M Green, Bart GP Koot, Gill Levitt, László Szonyi, W Hamish Wallace, Roderick Skinner, Mel Source Type: research
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
About 22,000 new cases of ovarian carcinomas are detected every year in the US [1]. It is considered that around 65% to 80% of patients are diagnosed with advanced stages III-IV diseases, depending on the pathology subtypes [1]. The backbone of the standard first-line treatment has historically relied on two components, with the combination of debulking surgery and systemic medical therapy. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 14, 2021 Category: Cancer & Oncology Authors: Benoit You, Gilles Freyer, Antonio Gonzalez-Martin, Stephanie Lheureux, Iain McNeish, Richard T Penson, Sandro Pignata, Eric Pujade-Lauraine Source Type: research
The Impact of Radiological Assessment Schedules on Progression-Free Survival in Metastatic Breast Cancer: A Systemic Review and Meta-Analysis
The main objectives of treating metastatic cancer are to prolong survival and to improve quality of life. While overall-survival (OS) is considered the gold standard for demonstrating clinical benefit in oncology trials, the U.S. Food and Drug Administration (FDA) accepts intermediate endpoints for clinical benefit when considering drugs for approval [1]. Progression-free survival (PFS) is used increasingly as a primary endpoint in cancer randomized controlled trials (RCTs) [2]. PFS may shorten the required duration of follow-up, quicken the time to drug approval and reduce costs [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 13, 2021 Category: Cancer & Oncology Authors: Dor Reuven Dabush, Daniel Shepshelovich, Tzippy Shochat, Ariadna Tibau, Eitan Amir, Hadar Goldvaser Source Type: research
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers and is well known for high incidence of brain metastases (BMs). BM has been reported at an incidence rate of 10 – 20% at diagnosis and ∼25% during the course of the disease.[1–3] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 11, 2021 Category: Cancer & Oncology Authors: Jiyun Lee, Myung-Ju Ahn Source Type: research
